CANTOR (NCT06792695) is an open-label, multicenter Phase II master protocol designed to evaluate the safety and efficacy of novel investigational combinations in patients with metastatic colorectal cancer. In the evaluated substudy, participants are randomized to volrustomig plus FOLFIRI and bevacizumab versus FOLFIRI and bevacizumab alone. The trial’s primary focus is on safety and assessment of the combination’s anti-tumour activity, with secondary endpoints addressing key efficacy outcomes and response metrics. Eligible subjects are adults with metastatic colorectal cancer; the platform design enables sequential comparison of additional combinations against an active control.
This Phase II study evaluates whether adding the investigational drug volrustomig to the standard FOLFIRI plus bevacizumab regimen is safe and effective for adults with metastatic colorectal cancer. Participants are assigned to either volrustomig plus FOLFIRI/bevacizumab or FOLFIRI/bevacizumab alone. The study aims to assess safety and the anti-tumor activity of the combination. It is an open-label, multicenter master protocol enrolling adults with metastatic colorectal cancer. Secondary measures include key efficacy outcomes and overall treatment response.
